Insulin‐like growth factor‐I, insulin‐like growth factor binding protein‐3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial
- 10 July 2008
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 68 (13), 1477-1486
- https://doi.org/10.1002/pros.20819
Abstract
BACKGROUND We investigated whether peptides involved in cellular proliferation and apoptosis, [insulin‐like growth factor I (IGFI) and its major binding protein (insulin‐like growth factor binding protein 3)], predicted risk of benign prostate hyperplasia (BPH). METHODS We conducted a nested‐case–control study in the placebo arm of the prostate cancer prevention trial (PCPT). Cases (n = 727) were men with surgical or medical treatment for BPH; two or more IPSS scores >14; or two scores of at least five points over baseline one of which was ≥12. Controls (n = 727) were frequency matched by age to cases, reported no BPH treatment, and no IPSS score >8. Cases and controls remained on the PCPT placebo and were followed closely until their 7‐year PCPT anniversary. Baseline serum was analyzed for IGFI and IGFBP3. Unconditional logistic regression and polytomous regression estimated the multivariate‐adjusted odds ratio (OR) for BPH risk. RESULTS IGFBP3 was inversely and the IGFI:IGFBP3 ratio was positively associated with BPH risk, but findings were statistically significant only for men with severe symptoms (OR = 0.60, 95% CI = 0.40–0.90 for the fifth vs. first quintile of IGFBP3, P‐trend = 0.01). Associations did not differ by age (<65 or ≥65 years), and there was a suggestion that the IGFI:IGFBP3 – BPH risk association may be stronger among overweight men. CONCLUSIONS A high IGFI:IGFBP3 ratio was associated with increased BPH risk, and high serum IGFBP3 was associated with decreased BPH risk among men with severe symptoms. These results confirm findings from other recent studies. Prostate 68: 1477–1486, 2008.This publication has 40 references indexed in Scilit:
- Hormonal profile of diabetic men and the potential link to prostate cancerCancer Causes & Control, 2008
- Association of IGF-1 and IGFBP-3 with lower urinary tract symptoms in the third national health and nutrition examination surveyThe Prostate, 2007
- Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesisOncogene, 2006
- Insulin-like growth factors and neoplasiaNature Reviews Cancer, 2004
- Serum Insulin-Like Growth Factor-I and Insulin-Like Growth Factor-Binding Protein-3 in Localized, Metastasized Prostate Cancer and Benign Prostatic HyperplasiaUrologia Internationalis, 2004
- Association between Insulin-Like Growth Factor-ICancer Epidemiology, Biomarkers & Prevention, 2004
- Effect of Two Years of Growth Hormone and Insulin-Like Growth Factor-I Suppression on Prostate Diseases in Acromegalic PatientsJournal of Clinical Endocrinology & Metabolism, 2000
- Role of the Insulin-Like Growth Factor Family in Cancer Development and ProgressionJNCI Journal of the National Cancer Institute, 2000
- Prostatic Hyperplasia: An Unknown Feature of AcromegalyJournal of Clinical Endocrinology & Metabolism, 1998
- The IGF Axis in the ProstateHormone and Metabolic Research, 1994